Ribonucleotide reductase expression in cervical cancer: A Radiation Therapy Oncology Group translational science analysis

International Journal of Gynecological Cancer

Volumn 23, Issue 4, 2013, Pages 615-621

  Kunos, Charles A ^a   Winter, Kathryn ^b   Dicker, Adam P ^c   Small, William ^d   Abdul Karim, Fadi W ^e   Dawson, Dawn ^a   Jhingran, Anuja ^f   Valicenti, Richard ^g   Weidhaas, Joanne B ^h   Gaffney, David K ⁱ  

^a UNIVERSITY HOSPITALS OF CLEVELAND   (United States)

^b RTOG Statistical Center   (United States)

^c THOMAS JEFFERSON UNIVERSITY   (United States)

^d NORTHWESTERN UNIVERSITY   (United States)

^e LERNER RESEARCH INSTITUTE   (United States)

^f UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^g UNIVERSITY OF CALIFORNIA   (United States)

^h YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

ⁱ UNIVERSITY OF UTAH HEALTH SCIENCES CENTER   (United States)

Author keywords

Cervical cancer; Radiosensitivity; Ribonucleotide reductase

Indexed keywords

AMIFOSTINE; CELECOXIB; CISPLATIN; FLUOROURACIL; RIBONUCLEOTIDE REDUCTASE;

ADULT; AGED; ARTICLE; BRACHYTHERAPY; CANCER STAGING; CHEMORADIOTHERAPY; CLINICAL TRIAL (TOPIC); DISEASE FREE SURVIVAL; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; MAJOR CLINICAL STUDY; OVERALL SURVIVAL; PELVIS LYMPH NODE; PRIORITY JOURNAL; PROTEIN EXPRESSION; UTERINE CERVIX CANCER;

EID: 84879912271     PISSN: 1048891X     EISSN: 15251438     Source Type: Journal    
DOI: 10.1097/IGC.0b013e31828b4eb5     Document Type: Article

References (30)

1. Kunos C, Chiu S, Pink J, et al. Modulating radiation resistance by inhibiting ribonucleotide reductase in cancers with virally or mutationally silenced p53 protein. Radiat Res. 2009;172:666-676.
2. Kunos C, Radivoyevitch T, Pink J, et al. Ribonucleotide reductase inhibition enhances chemoradiosensitivity of human cervical cancers. Radiat Res. 2010;174:574-581.
3. Kunos C, Colussi V, Pink J, et al. Radiosensitization of human cervical cancer cells by inhibiting ribonucleotide reductase: enhanced radiation response at low dose rates. Int J Radiat Oncol Biol Phys. 2011;80:1198-1204.
4. Kunos C, Ferris G, Pyatka N, et al. Deoxynucleoside salvage facilitates DNA repair during ribonucleotide reductase blockade in human cervical cancers. Radiat Res. 2011;176:425-433.
5. Kunos C, Waggoner S, Von Gruenigen V, et al. Phase I trial of intravenous 3-aminopyridine-2-carboxaldehyde thiosemicarbazone (3-AP, NSC #663249) in combination with pelvic radiation therapy and weekly cisplatin chemotherapy for locally advanced cervical cancer. Clin Cancer Res. 2010;16:1298-1306.
6. Kunos C, Waggoner S, Zanotti K, et al. Phase 2 trial of pelvic radiation, weekly cisplatin, and 3-aminopyridine-2-carboxaldehyde thiosemicarbazone (3-AP, NSC #663249) for locally advanced cervical and vaginal cancer. J ClinOncol. 2011;29: abstract #5034.
7. Kunos C,Ali S, Abdul-KarimF, et al. Posttherapy residual disease associates with long-term survival after chemoradiation for bulky stage 1B cervical carcinoma: a Gynecologic Oncology Group Study. Am J Obstet Gynecol. 2010;203:351.e1-351.e8.
8. Rose P, Ali S, Whitney C, et al. Outcome of stage IVA cervical cancer patients with disease limited to the pelvis in the era of chemoradiation: a Gynecologic Oncology Group study. Gynecol Oncol. 2011;121:542-545.
9. Kunos C. Therapeutic mechanisms of treatment in cervical and vaginal cancer. Oncol Hematol Rev. 2012;8:55-60.
10. Hakansson P, Hofer A, Thelander L. Regulation of mammalian ribonucleotide reduction and dNTP pools after DNA damage and in resting cells. J Biol Chem. 2006;281:7834-7841.
11. HreshchyshynMM, Aron BS, Boronow RC, et al. Hydroxyurea or placebo combinedwith radiation to treat stages IIIB and IV cervical cancer confined to the pelvis. Int J Radiat Oncol Biol Phys. 1979; 5:317-322.
12. Whitney CW, SauseW, Bundy BN, et al. Randomized comparison of fluorouracil plus cisplatin versus hydroxyurea as an adjunct to radiation therapy in stage IIB-IVA carcinoma of the cervix with negative para-aortic lymph nodes: a Gynecologic Oncology Group and Southwest Oncology Group study. J Clin Oncol. 1999; 17:1339-1348.
13. Rose P, Ali S,Watkins E, et al. Long-termfollow-up of a randomized trial comparing concurrent single agent cisplatin, cisplatin-based combination chemotherapy, or hydroxyurea during pelvic irradiation for locally advanced cervical cancer: a GynecologicOncologyGroup Study. J Clin Oncol. 2007;25:2804-2810.
14. Eifel PJ, Winter K, Morris M, et al. Pelvic irradiation with concurrent chemotherapy versus pelvic and para-aortic irradiation for high-risk cervical cancer: an update of radiation therapy oncology group trial (RTOG) 90-01. J Clin Oncol. 2004; 22:872-880.
15. Duenas-Gonzalez A, Zarba J, Patel F, et al. A phase III, open-label, randomized study comparing concurrent gemcitabine plus cisplatin and radiation followed by adjuvant gemcitabine and cisplatin versus concurrent cisplatin and radiation in patients with stage IIB to IVA carcinoma of the cervix. J Clin Oncol. 2011;29:1678-1685.
16. Small W Jr, Winter K, Levenback C, et al. Extended-field irradiation and intracavitary brachytherapy combined with cisplatin chemotherapy for cervical cancer with positive para-aortic or high common iliac lymph nodes: results of Arm 1 of RTOG 0116. Int J Radiat Oncol Biol Phys. 2007;68:1081-1087.
17. Gaffney D, Winter K, Dicker A, et al. A phase 2 study of acute toxicity of Celebrexi (celecoxib) and chemoradiation in patients with locally advanced cervical cancer: primary endpoint analysis of RTOG 0128. Int J Radiat Oncol Biol Phys. 2007;67: 104-109.
18. Gaffney D, Winter K, Dicker A, et al. Efficacy and patterns of failure for locally advanced cancer of the cervix treated with Celebrex (celecoxib) and chemoradiotherapy in RTOG 0128. Int J Radiat Oncol Biol Phys. 2007;69:111-117.
19. Kunos C, Radivoyevitch T, Kresak A, et al. Elevated ribonucleotide reductase levels associate with suppressed radiochemotherapy response in human cervical cancers. Int J Gynecol Cancer. 2012;22:1463-1469. doi:10.097/IGC. 0b013e318270577f.
20. Pontarin G, Ferraro P, Rampazzo C, et al. Deoxyribonucleotide metabolism in cycling and resting human fibroblasts with a missense mutation in p53R2, a subunit of ribonucleotide reductase. J Biol Chem. 2011;286:11132-11140.
21. Pontarin G, Fijolek A, Pizzo P, et al. Ribonucleotide reduction is a cytosolic process in mammalian cells independently of DNA damage. Proc Natl Acad Sci U S A. 2008;105:17801-17806.
22. Kaplan E, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc. 1958;53:457-481.
23. Cox D. Regression models and life tables (with discussion). J R Stat Soc. 1972;34:187-220.
24. Engstrom Y, Erriksson S, Jildevik I, et al. Cell cycle-dependent expression of mammalian ribonucleotide reductase. Differential regulation of the two subunits. J Biol Chem. 1985;26: 9114-9116.
25. Mann G, Musgrove E, Fox R, et al. Ribonucleotide reductase M1 subunit in cellular proliferation, quiescence, and differentiation. Cancer Res. 1988;48:5151-5156.
26. Chabes A, Thelander L. Controlled protein degradation regulates ribonucleotide reductase activity in proliferating mammalian cells during the normal cell cycle and in response to DNA damage and replication blocks. J Biol Chem. 2000;275: 17747-17753.
27. Chabes A, Pfleger C, Kirschner M, et al. Mouse ribonucleotide reductase R2 protein: a new target for anaphase-promoting comploex-Cdh1-mediated proteolysis. Proc Natl Acad Sci U S A. 2003;100:3925-3929.
28. Tanaka H, Arakawa H, Yamaguchi T, et al. A ribonucleotide reductase gene involved in a p53-dependent cell-cycle checkpoint for DNA damage. Nature. 2000;404:42-49.
29. Xue L, Zhou B, Liu X, et al. Wild-type p53 regulates human ribonucleotide reductase by protein-protein interaction with p53R2 as well as hRRM2 subunits. Cancer Res. 2003;63: 980-986.
30. Zhou B, Liu X, Mo X, et al. The human ribonucleotide reductase subunit hRRM2 complements p53R2 in response to UV-induced DNA repair in cells with mutant p53. Cancer Res. 2003;63:6583-6594.